中国中医药信息杂志2025，Vol.32Issue(5)：162-167,6.DOI:10.19879/j.cnki.1005-5304.202409330
补益脾肾方联合西医常规疗法治疗原发性慢性肾脏病3期脾肾气虚证临床研究
Clinical Study on Buyi Pishen Prescription Combined with Conventional Western Medicine Therapy for Treatment of Primary Chronic Kidney Disease Stage 3 with Spleen and Kidney Qi Deficiency Syndrome
摘要
Abstract
Objective To observe the efficacy and safety of Buyi Pishen Prescription combined with alisartan ester tablets in patients with primary chronic kidney disease stage 3(CKD3)with spleen-kidney qi deficiency syndrome.Methods Totally 80 patients were divided into treatment group and control group using a random number table method,with 40 cases in each group.Both groups received basic treatment and alisartan ester tablets(1 tablet/day,once daily,orally).The treatment group additionally received the Buyi Pishen Prescription(1 dosage/day,twice daily,orally).Both groups were treated for 24 weeks.TCM syndrome efficacy and clinical efficacy were evaluated.At 8,16 and 24 weeks,24-hour urinary protein(24 hUpro),serum creatinine(SCr),blood urea nitrogen(BUN),estimated glomerular filtration rate(eGFR)and TCM syndrome scores were measured.Serum oxidative stress markers(SOD,GSH-Px,MDA)were assessed before and after treatment.Blood potassium and liver function were monitored throughout.Results The total effective rate for TCM syndrome efficacy was 82.50%(33/40)in the treatment group and 60.00%(24/40)in the control group(P<0.05),and the treatment group was better than the control group.The total clinical efficacy rate was 77.50%(31/40)in the treatment group and 50.00%(20/40)in the control group,and the treatment group was better than the control group(P<0.05).Compared with before treatment,the treatment group showed a significant decrease in 24 hUpro and SCr at weeks 8,16 and 24,a significant decrease in BUN at weeks 16 and 24,and a significant increase in eGFR at weeks 8,16 and 24(P<0.01);the control group showed a decrease in 24 hUpro at weeks 8,16 and 24 of treatment(P<0.05),a decrease in SCr at weeks 16 and 24 of treatment(P<0.05),and an increase in eGFR at weeks 16 and 24 of treatment(P<0.05).In addition,the treatment group had lower 24 hUpro and SCr at weeks 16 and 24 of treatment than the control group(P<0.05,P<0.01),and higher eGFR than the control group(P<0.05,P<0.01).Compared with before treatment,the total scores of both the treatment group and control group significantly decreased at 16 and 24 weeks of treatment(P<0.01).The total scores of the treatment group were significantly lower than those of the control group at 8,16 and 24 weeks of treatment(P<0.01).Compared with before treatment,both groups showed a significant increase in serum SOD levels(P<0.05,P<0.01)and a significant decrease in MDA levels after treatment(P<0.05,P<0.01).The improvement in the treatment group was more significant than that in the control group(P<0.05).Both groups showed no abnormalities in blood potassium and liver function.Conclusion Buyi Pishen Prescription combined with alisartan ester tablets can reduce the levels of 24 hUpro,BUN and SCr,improve eGFR,alleviate TCM symptoms,and delay CKD progression in CKD3 patients with spleen-kidney qi deficiency syndrome,which can effectively reduce the serum MDA level and increase the antioxidant enzyme SOD level in patients,and its mechanism may be related to improving oxidative stress levels.关键词
慢性肾脏病3期/补益脾肾方/临床疗效/氧化应激Key words
chronic kidney disease stage 3/Buyi Pishen Prescription/clinical efficacy/oxidative stress分类
医药卫生引用本文复制引用
王杰,何立群,姚兴梅,方际,王浩..补益脾肾方联合西医常规疗法治疗原发性慢性肾脏病3期脾肾气虚证临床研究[J].中国中医药信息杂志,2025,32(5):162-167,6.基金项目
上海市卫生健康委员会中医药科研项目(2024QN080) （2024QN080）
上海市普陀区卫生健康系统临床特色专科(肾内科)(2021tszk02) （肾内科）
上海市普陀区卫生健康系统科技创新项目(ptkwws202311) （ptkwws202311）
